Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study
PLOS ONE · 27.02.2024 · 19 (2) · e0298573
DOI: 10.1371/journal.pone.0298573 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, online erschienen am 27.02.2024. Verfasst von Shunsuke Mori und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Ko…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Lung Neoplasms, Pulmonary Emphysema, Lung Diseases, Interstitial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital Organization, Japan, AbbVie GK, Asahikasei Pharma Corp..
Abstract (Originalsprache)
Objective
Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome characterized by the coexistence of emphysema and fibrotic interstitial lung disease (ILD). The aim of this study was to examine the effect of CPFE on lung cancer risk and lung cancer-related mortality in patients with rheumatoid arthritis (RA).
Methods
We conducted a multicenter retrospective cohort study of patients newly diagnosed with lung cancer at five community hospitals between June 2006 and December 2021. Patients were followed until lung cancer-related death, other-cause death, loss to follow-up, or the end of the study. We used the cumulative incidence function with Gray’s test and Fine-Gray regression analysis for survival analysis.
Results
A total of 563 patients with biopsy-proven lung cancer were included (82 RA patients and 481 non-RA patients). The prevalence of CPFE was higher in RA patients than in non-RA patients (40.2% vs.10.0%) at lung cancer diagnosis. During follow-up, the crude incidence rate of lung cancer-related death was 0.29 and 0.10 per patient-year (PY) in RA and non-RA patients, and 0.32 and 0.07 per PY in patients with CPFE and patients without ILD or emphysema, respectively. The estimated death probability at 5 years differed between RA and non-RA patients (66% vs. 32%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi, Kumamoto, Japan.
- Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan.
- Department of Respiratory Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan.
- Department of Respiratory Medicine, NHO Kumamoto Saishun Medical Center, Kohshi, Kumamoto, Japan.
- Department of Radiology, NHO Kumamoto Saishun Medical Center, Kohshi, Kumamoto, Japan.
- Institute of Rheumatology, Miyazaki-Zenjinkai Hospital, Miyazaki, Japan.
ORCID-Profile: Shunsuke Mori
Förderung
- National Hospital Organization, Japan
- AbbVie GK
- Asahikasei Pharma Corp.
- Chugai Pharmaceutical Co. Ltd.
Zitieren
APA
Mori, S., Ueki, Y., Hasegawa, M., Nakamura, K., Nakashima, K., Hidaka, T., Ishii, K., Kobayashi, H., & Miyamura, T. (2024). Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study. PLOS ONE, 19(2), e0298573. https://doi.org/10.1371/journal.pone.0298573
Vancouver
Mori S, Ueki Y, Hasegawa M, Nakamura K, Nakashima K, Hidaka T, et al. Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study. PLOS ONE. 2024;19(2):e0298573. doi:10.1371/journal.pone.0298573
BibTeX
@article{Mori2024,
author = {Mori, Shunsuke and Ueki, Yukitaka and Hasegawa, Mizue and Nakamura, Kazuyoshi and Nakashima, Kouya and Hidaka, Toshihiko and Ishii, Koji and Kobayashi, Hironori and Miyamura, Tomoya},
title = {Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {2},
pages = {e0298573},
doi = {10.1371/journal.pone.0298573}
}
EUVIMED